Home > Publications Database > Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive. > print

001     155828
005     20230915092342.0
024 7 _ |a 10.1016/j.jclinepi.2020.10.008
|2 doi
024 7 _ |a pmid:33068714
|2 pmid
024 7 _ |a pmc:PMC7554475
|2 pmc
024 7 _ |a 0895-4356
|2 ISSN
024 7 _ |a 1878-5921
|2 ISSN
024 7 _ |a altmetric:92385848
|2 altmetric
037 _ _ |a DZNE-2021-00988
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ewers, Michael
|0 P:(DE-2719)9000543
|b 0
|e First author
|u dzne
245 _ _ |a Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive.
260 _ _ |a Amsterdam [u.a.]
|c 2021
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1631276561_6055
|2 PUB:(DE-HGF)
|x Editorial
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Hydroxychloroquine
|0 4QWG6N8QKH
|2 NLM Chemicals
650 _ 2 |a COVID-19 Drug Treatment
|2 MeSH
650 _ 2 |a COVID-19: drug therapy
|2 MeSH
650 _ 2 |a COVID-19: mortality
|2 MeSH
650 _ 2 |a Clinical Trials as Topic: standards
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Hydroxychloroquine: adverse effects
|2 MeSH
650 _ 2 |a Hydroxychloroquine: therapeutic use
|2 MeSH
650 _ 2 |a Information Dissemination
|2 MeSH
650 _ 2 |a Medical Records
|2 MeSH
650 _ 2 |a Observational Studies as Topic: standards
|2 MeSH
650 _ 2 |a Open Access Publishing
|2 MeSH
650 _ 2 |a Survival Analysis
|2 MeSH
650 _ 2 |a Time Factors
|2 MeSH
700 1 _ |a Ioannidis, John P A
|b 1
700 1 _ |a Plesnila, Nikolaus
|0 P:(DE-2719)9000853
|b 2
|u dzne
773 _ _ |a 10.1016/j.jclinepi.2020.10.008
|g Vol. 130, p. 143 - 146
|0 PERI:(DE-600)1500490-9
|p 143 - 146
|t Journal of clinical epidemiology
|v 130
|y 2021
|x 0895-4356
909 C O |o oai:pub.dzne.de:155828
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000543
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)9000853
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-30
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-30
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN EPIDEMIOL : 2021
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-30
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-30
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J CLIN EPIDEMIOL : 2021
|d 2022-11-30
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1110008
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21